$2.12 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GTXI | Exit | GTX INC DELcall | $0 | – | -50,000 | -100.0% | -0.00% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -820,000 | -100.0% | -0.04% | – |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -100,000 | -100.0% | -0.04% | – |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -0.05% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -220,000 | -100.0% | -0.06% | – |
| MNLO | Exit | MENLO THERAPEUTICS INC | $0 | – | -330,000 | -100.0% | -0.12% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -17,665 | -100.0% | -0.12% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.13% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -187,500 | -100.0% | -0.15% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -900,000 | -100.0% | -0.20% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -975,000 | -100.0% | -0.22% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -405,000 | -100.0% | -0.26% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -92,500 | -100.0% | -0.29% | – |
| ELAN | Exit | ELANCO ANIMAL HEALTH INC | $0 | – | -375,000 | -100.0% | -0.47% | – |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -850,000 | -100.0% | -0.55% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -375,000 | -100.0% | -0.62% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -325,000 | -100.0% | -1.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.